Table 5 Components of Q-TWiST

From: Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

 

Treatment group

Health state

Tam alone (s.e.)

CMF → Tam (s.e.)

Difference (s.e.)

(95% CI)

P

Tox

     

 Overall

>0 (0)

>1.7 (0.1)

—

—

—

 ER-negative

>0 (0)

>1.8 (0.1)

—

—

—

 ER-positive

>0 (0)

>1.7 (0.1)

—

—

—

TWiST

     

 Overall

>63.4 (0.7)

>64.0 (0.6)

—

—

—

 ER-negative

>57.7 (1.7)

>62.6 (1.4)

—

—

—

 ER-positive

>65.4 (0.7)

>64.2 (0.7)

—

—

—

Rel

     

 Overall

>5.1 (0.5)

>3.8 (0.4)

—

—

—

 ER-negative

>7.5 (1.2)

>3.3 (0.9)

—

—

—

 ER-positive

>4.5 (0.6)

>4.2 (0.6)

—

—

—

Q-TWiST

     

 Overall

>61.4 (0.4)

>62.5 (0.3)

>1.1 (0.5)

(0.1–2.1)

0.03

 ER-negative

>57.8 (1.1)

>60.8 (1.0)

>3.0 (1.4)

(0.2–5.8)

0.03

 ER-positive

>62.7 (0.4)

>63.0 (0.4)

>0.3 (0.5)

(−0.6–1.3)

0.50

  1. Averaged months of Tox, TWiST and Rel accumulated within 72 months of randomisation, with Q-TWiST calculated for patient-derived utility coefficients (N=1669). s.e.=standard error; ER=oestrogen receptor.
Back to article page